Lexeo Therapeutics, Inc. LXEO
2.95 USD 0.00 (+0.00%)
Regular-session close
2.92 -0.03 -1.02%
Pre-market · Nov 20, 8:50 AM ET
2.87 Day range 3.21
2.55 52-week range 10.99
- YTD
- -70.29%
- 1 year
- -67.55%
News
seekingalpha.com Lexeo Therapeutics: Encouraging Gene Therapy Data, But I Want To See More Lexeo Therapeutics has two promising gene therapy candidates with LX2006 and LX2020. There are rather encouraging early clinical results and some potential to address underlying disease mechanisms.…
benzinga.com Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study Lexeo Therapeutics Inc. (NASDAQ:LXEO) on Monday announced positive interim results from its ongoing HEROIC-PKP2 Phase 1/2 trial evaluating LX2020 in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) and…
benzinga.com Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study Lexeo Therapeutics reports an 80% mean arrhythmia reduction in its Phase 1/2 LX2020 heart trial and targets a pivotal trial in late 2027.
marketbeat.com Lexeo Therapeutics Q3 Earnings Call Highlights Lexeo Therapeutics NASDAQ: LXEO reported interim data from a small, early-stage trial of its gene therapy LX2020, saying patients who received the higher dose showed reductions in abnormal heart…benzinga.com Cantor Fitzgerald Maintains Overweight on Lexeo Therapeutics, Raises Price Target to $37 Cantor Fitzgerald analyst Kristen Kluska maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and raises the price target from $23 to $37.
benzinga.com Lexeo Therapeutics Announces Interim Data From Its Ongoing HEROIC-PKP2 Phase I/II Clinical Trial Of LX2020 For Treatment Of PKP2 Arrhythmogenic Cardiomyopathy; Across Ten Participants, Including Nine With At Least 12 Months Of Follow-up, Treatment With LX2020 Was Generally Well Tolerated Across ten participants, including nine with at least 12 months of follow-up, treatment with LX2020 was generally well tolerated and associated with clinically meaningful reductions in arrhythmia…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Akanda (NASDAQ:AKAN) shares increased by 55.1% to $2.11 during Monday's pre-market session. The market value of their outstanding shares is at $3.5 million. Alpha Tau Medical (NASDAQ:DRTS)…benzinga.com Lexeo Therapeutics Q3 EPS $(0.43) Misses $(0.33) Estimate Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.33) by 30.3 percent. This is a 30.3 percent decrease over losses of…
globenewswire.com Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and 44% mean reduction in premature ventricular contractions at latest assessment LX2020…
globenewswire.com Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026 NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced…
